IBD Stem Cell Culture System for Disease Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Crohn's disease and other inflammatory bowel diseases (IBD) are inadequate, as they primarily focus on symptom control rather than addressing the underlying disease mechanisms, and there is a need for more effective therapeutic targets.
Innovation Solution
The isolation and maintenance of epithelial stem cells derived from gastrointestinal biopsies of IBD patients, using a culture media system that includes ROCK inhibitors, Wnt agonists, BMP antagonists, Notched inhibitors, TGFβ signaling pathway inhibitors, and nicotinamide, to create stable and viable IBD stem cell cultures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional symptom control treatments are used for IBD, then immediate symptom relief is achieved, but the underlying disease mechanisms are not addressed and disease progression continues
Solution Approach 1:
The patent extracts and isolates intestinal stem cells from IBD patient biopsies, separating the fundamental disease-causing cells from the complex inflammatory environment. This allows direct study and potential targeting of the root cause rather than treating downstream symptoms, enabling disease modification by addressing the origin of the pathology.
Solution Approach 2:
The patent performs preliminary characterization of IBD stem cells, including gene expression profiling and functional analysis, before developing therapies. This advance understanding of stem cell properties and disease mechanisms enables more effective targeted treatments to be developed sooner, reducing the time to address the root cause.
2Loss of information
If stem cells are isolated from IBD patient biopsies, then direct study of disease mechanisms is enabled, but the isolation and culture process is highly complex and technically challenging
Solution Approach 1:
The patent uses feeder cells as an intermediary component to support the growth and maintenance of IBD stem cells in culture. These feeder cells provide necessary signals and a physiological environment that enables stem cell survival and proliferation without requiring complex artificial culture systems, thereby simplifying the overall isolation and culture process while preserving disease mechanism information.
3Reliability
If targeted therapies are developed based on IBD stem cell research, then effective disease-modifying treatments can be created, but the translation from research to clinical application takes significant time
Solution Approach 1:
The patent creates in vitro models by culturing and propagating IBD stem cells that replicate the disease state. These cellular copies serve as surrogate systems for testing potential therapies, allowing multiple drug candidates to be screened and optimized in the laboratory before clinical trials. This copying approach accelerates the translation process by enabling parallel testing of multiple therapeutic strategies without waiting for clinical trial results.
Data Source
AI summary
The present invention addresses IBD from the standpoint of mucosal stem cells cloned from defined regions of the gastrointestinal tract. In the case of pediatric Crohn's disease, for example, isolation of those stem cells according to the methods of the present invention reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.